Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost

Publisher： Karger

E-ISSN： 1421-9875|35|1-2|61-68

ISSN： 0257-2753

Source： Digestive Diseases, Vol.35, Iss.1-2, 2017-02, pp. : 61-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases

By Zelinkova Zuzana   Mensink Peter BF   Dees Jan   Kuipers Ernst J.   van der Woude Christien J.  

Scandinavian Journal of Gastroenterology, Vol. 45, Iss. 1, 2010-01 ,pp. : 46-50

Informa Healthcare

Access to resources Recommend Favorite

Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease

By  

Digestive Diseases, Vol. 33, Iss. 1, 2015-09 ,pp. : 70-77

Karger

Access to resources Recommend Favorite

Drug Monitoring in Inflammatory Bowel Disease: Helpful or Dispensable?

By  

Digestive Diseases, Vol. 27, Iss. 3, 2009-09 ,pp. : 394-403

Karger

Access to resources Recommend Favorite

Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?

By  

Digestive Diseases, Vol. 34, Iss. 1, 2016-08 ,pp. : 74-81

Karger

Access to resources Recommend Favorite

Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 34, Iss. 5, 2016-06 ,pp. : 552-557

Karger

Access to resources Recommend Favorite